

The Goldman Guide

August 28, 2011

Volume 2, Number 15

In This Issue

It's Always Something

Making a List, Checking it
Twice

Sunsi Energies, Inc. (OTCQB-
SSIE)

Nuvilex, Inc. (OTCQB-NVLX)

Oculus Innovative Sciences,
Inc. (NASDAQ-OCLS)

OHR Pharmaceutical, Inc.
(OTCBB-OHRP)

Contact Us

www.goldmanresearch.com

It's Always Something

I apologize in advance for the short edition of *The Goldman Guide*. Then again, some of you are probably praising the decision. As I write this, the winds are howling outside as the outer band of what is left of Hurricane Irene starts to hit the Baltimore area. I already have a small leak, but I am thankful we are pretty far inland so the weather should not be as bad as on the Eastern Shore.

It got me thinking. During the past 18 months, this area has been hit by 2 blizzards, days apart (early February 2010) a real heat wave, and in less than a week, an earthquake and hurricane.

I shudder to think what is next.

During this time, the market has had some serious ups (early 2010), Flash Crash (May 2010), major ups (4Q10 – 1Q11), big down periods, (May – June 2011) and the fun August.

We have endured a lousy economy, horrific housing and unemployment, sovereign debt issues, budget battles, a series of oil spikes, the death of Osama Bin Laden, the Arab Spring, and a host of other events here and abroad, too long to list.

Right now, confidence is shaken and the future is foggy. The market looks like an EKG, with the slightest bit of good, bad, or odd news having an impact, or rather, a knee-jerk reaction. Too much anxiety. It just seems like it's always something.

Making a List, Checking it Twice

Well, it ain't changing, hon. This volatility, that is. On all these fronts. I, for one, am not going to sit here and just roll with the punches. As far as I am concerned, while everyone is treating each day like it is to be feared, or like Halloween, I am looking ahead.

For me, it's like Christmas. And I plan on buying. Not today, but as I get closer to the big day. But I think we should all think about bottom fishing.

We should all be making our list and checking it twice. Monitor the market before stepping in. Try to make purchases only after you are convinced the market is not naughty but nice. Even if it is temperamental.

I will be putting out my bottom fishing and watch list next week. If you wish to share one, please email me rob@goldmanresearch.com.

The End of Summer...How'd We Do?

After glossing over some just awful performance numbers in general, I thought it might be a good idea to see how our recommendations have performed during this summer rollercoaster.

I am pleased to say that we trounced any and all benchmarks. For the purposes of this look-back, "Summer" is quantified by the period beginning May 27, 2011 (Memorial Day Weekend) through August 26, 2011.

GSCR 2011 Summer Scorecard							
Stock	Init Price	Aug Price	Change		May Price	Aug Price	Change
SSIE	\$3.10	\$3.74	20.6%		\$3.10	\$3.74	20.6%
NVLX	\$0.026	\$0.052	100.0%		\$0.060	\$0.052	-13.3%
OCLS*	\$1.60	\$1.33	-16.9%		\$1.60	\$1.33	-16.9%
OHRP**	\$0.42	\$0.74	76.2%		\$0.42	\$0.74	76.2%
Average			45.0%	Average	16.7%		
				Rus 2000	836.26	691.79	-17.3%
*We initiated coverage on OCLS 6/20/11.							
**We re-introduced coverage on OHRP on 6/21/11.							

As illustrated in this crude table, our picks as of the initiation dates as a whole have done remarkable well. SSIE and NVLX were released in mid-May, and OCLS was released on June 20, 2011. OHRP was re-introduced on 6/21/11.

I am especially pleased to note that the summer performance is outstanding. The Russell 2000 during this period was down 17% versus our 16% gain. Even if the dates were modified for OCLS and OHRP, the numbers would be nearly identical, on an average return basis.

It should be noted that 3 of the 4 stocks are in the biomed space, and 2 in biotech. However, even when comparing our performance to small cap biotech indices (such as Burrill) their returns for the period are down roughly 13%, versus our gain.

On many occasions, we have noted that it is a stock-picker's market and it should remain so. We recommend these 4 stocks at these levels and believe that individually and collectively, they will continue to outperform.

Make your list, and be on the lookout for ours...

Until next week....

Analyst: Robert Goldman

Rob Goldman has over 20 years of investment and company research experience as a senior research analyst and as a portfolio and mutual fund manager. During his tenure as a sell-side analyst, Rob was a senior member of Piper Jaffray's Technology and Communications teams. Prior to joining Piper, Rob led Josephthal & Co.'s Washington-based Emerging Growth Research Group. In addition to his sell-side experience Rob served as Chief Investment Officer of a boutique investment management firm and Blue and White Investment Management, where he managed Small Cap Growth portfolios and *The Blue and White Fund*.

Analyst Certification

I, Robert Goldman, hereby certify that the view expressed in this newsletter report accurately reflect my personal views about the subject securities and issuers. I also certify that no part of my compensation was, is, or will be, directly or indirectly, related to the recommendations or views expressed in this research report.

Disclaimer

This newsletter was prepared for informational purposes only. *Goldman Small Cap Research*, (a division of Two Triangle Consulting Group, LLC) produces research via two formats: *Goldman Select Research* and *Goldman Opportunity Research*. The *Select* product reflects the Firm's internally generated stock ideas while the *Opportunity* product reflects sponsored research reports.

It is important to note that while we may track performance separately, we utilize the same coverage criteria in determining coverage of all stocks in both research formats. Please view the company's individual disclosures for each engagement, which can be found in each company-specific report. All information contained in this newsletter and in our reports were provided by the Companies or generated from our own due diligence. Our analysts are responsible only to the public, and are paid in advance to eliminate pecuniary interests, retain editorial control, and ensure independence. Analysts are compensated on a per report basis and not on the basis of his/her recommendations. *Goldman Small Cap Research* has been compensated by the Sunsi Energies, Inc., Nuvilex, Inc, and OHR Pharmaceutical, for research service subscriptions. In addition, and a third-party compensated GSCR on behalf of Oculus Innovative Sciences, Inc. for a research services subscription. Please see the disclaimers on the company reports for further information.

The information used and statements of fact made have been obtained from sources considered reliable but we neither guarantee nor represent the completeness or accuracy. *Goldman Small Cap Research* did not make an independent investigation or inquiry as to the accuracy of any information provided by the Company, or other firms. *Goldman Small Cap Research* relied solely upon information provided by the Company through its filings, press releases, presentations, and through its own internal due diligence for accuracy and completeness. Such information and the opinions expressed are subject to change without notice. A *Goldman Small Cap Research* report, note, or newsletter is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed.

This report or newsletter does not take into account the investment objectives, financial situation, or particular needs of any particular person. This report or newsletter does not provide all information material to an investor's decision about whether or not to make any investment. Any discussion of risks in this presentation is not a disclosure of all risks or a complete discussion of the risks mentioned. Neither *Goldman Small Cap Research*, nor its parent, is registered as a securities broker-dealer or an investment adviser with the U.S. Securities and Exchange Commission or with any state securities regulatory authority.

ALL INFORMATION IN THIS REPORT OR NEWSLETTER IS PROVIDED "AS IS" WITHOUT WARRANTIES, EXPRESSED OR IMPLIED, OR REPRESENTATIONS OF ANY KIND. TO THE FULLEST EXTENT PERMISSIBLE UNDER APPLICABLE LAW, *TWO TRIANGLE CONSULTING GROUP, LLC* WILL NOT BE LIABLE FOR THE QUALITY, ACCURACY, COMPLETENESS, RELIABILITY OR TIMELINESS OF THIS INFORMATION, OR FOR ANY DIRECT, INDIRECT, CONSEQUENTIAL, INCIDENTAL, SPECIAL OR PUNITIVE DAMAGES THAT MAY ARISE OUT OF THE USE OF THIS INFORMATION BY YOU OR ANYONE ELSE (INCLUDING, BUT NOT LIMITED TO, LOST PROFITS, LOSS OF OPPORTUNITIES, TRADING LOSSES, AND DAMAGES THAT MAY RESULT FROM ANY INACCURACY OR INCOMPLETENESS OF THIS INFORMATION). TO THE FULLEST EXTENT PERMITTED BY LAW, *TWO TRIANGLE CONSULTING GROUP, LLC* WILL NOT BE LIABLE TO YOU OR ANYONE ELSE UNDER ANY TORT, CONTRACT, NEGLIGENCE, STRICT LIABILITY, PRODUCTS LIABILITY, OR OTHER THEORY WITH RESPECT TO THIS PRESENTATION OF INFORMATION.

For more information, visit our Disclaimer: www.goldmanresearch.com